微针流感疫苗市场- 按产品类型（实心、空心、涂层、溶解微针）、疫苗类型（三价、四价）、流感类型（甲型流感[H1N1、H3N1]、乙型流感）、全球预测（2024 - 2032）

Microneedle Flu Vaccine Market - By Product Type (Solid, Hollow, Coated, Dissolving Microneedle), Vaccine Type (Trivalent, Quadrivalent), Flu Type (Influenza A [H1N1, H3N1], Influenza B), Global Forecast (2024 - 2032)

出版日期: 2024年06月03日 | 出版商:

Global Market Insights Inc. | 英文 148 Pages | 商品交期: 2-3个工作天内

价格

简介目录

在开发更有效、更有效率的微针设计的研究活动不断增加的推动下，微针流感疫苗市场规模从 2024 年到 2032 年的复合年增长率将达到 6.1%。例如，2023年1月，CD Formulation推出了可溶性微针製备服务，以提高药物输送效率。可生物降解聚合物和金属等材料的进步正在增强流感疫苗的输送，同时减少浪费。微针涂层的创新也提高了疫苗的稳定性和功效，增加了产品需求。

微针流感疫苗市场分为产品类型、疫苗类型、流感类型和地区。

从产品类型来看，2024年至2032年，涂层微针细分市场的产业价值可能会出现强劲成长。，从而更容易为大量人群快速接种疫苗。微针技术、材料科学和疫苗配方领域的不断进步也推动了更有效和用户友好的涂层微针疫苗的开发。

根据流感类型，B 型流感细分市场的微针流感疫苗市场预计将在 2024 年至 2032 年期间以强劲的复合年增长率扩张。这些疫苗的设计目的是比传统的肌肉注射疼痛更轻、更容易注射，并且可能更有效。凭藉积极的监管框架，微针疫苗已成为流感疫苗接种的标准解决方案，可改善公共卫生结果并减轻季节性流感流行的负担。正在进行的研发也可能产生更有效和用户友好的疫苗接种选择。

从地区来看，由于政府的大力支持，预计亚太地区微针流感疫苗产业从 2024 年到 2032 年将实现利润丰厚的复合年增长率。该地区对无痛、方便且经济有效的疫苗接种方法的关注使微针疫苗成为改善公共卫生结果的有前途的解决方案。亚太地区人口众多且多样化，获得医疗保健的机会也各不相同，这也将有利于人们对产品的偏好。

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 中国
- 日本
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 南非
- 沙乌地阿拉伯
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

3M
Becton, Dickinson and Company
Corium International, Inc.
CosMED Pharmaceuticals Co., Ltd
FluGen, Inc
Sanofi

简介目录

Product Code: 9724

Microneedle Flu Vaccine Market size will witness 6.1% CAGR from 2024-2032, driven by rising research activities for the development of more effective and efficient microneedle designs. For example, in January 2023, CD Formulation introduced its dissolving microneedle preparation services for enhancing drug delivery efficiency. Advancements in materials, such as biodegradable polymers and metals, are enhancing the delivery of the flu vaccines while reducing waste. Innovations in coatings used on microneedles are also improving the stability and efficacy of vaccines, adding to the product demand.

The microneedle flu vaccine market is segmented into product type, vaccine type, flu type, and region.

In terms of product type, the industry value from the coated microneedle segment may witness strong growth from 2024 to 2032. As coated microneedle patches can be self-administered, they reduce the need for healthcare professionals, making it easier to vaccinate the large population quickly. The ongoing advances in microneedle technology, materials science, and vaccine formulation area also driving the development of more effective and user-friendly coated microneedle vaccines.

Based on flue type, the microneedle flu vaccine market from the influenza B segment is expected to expand at robust CAGR from 2024-2032. These vaccines are designed to be less painful, easier to administer, and potentially more effective than traditional intramuscular injections. With positive regulatory frameworks, microneedle vaccines have turned standard solutions for influenza vaccination for improving public health outcomes and reducing the burden of seasonal flu epidemics. The ongoing R&D is also likely to yield more effective and user-friendly vaccination options.

Regionally, the Asia Pacific microneedle flu vaccine industry is projected to witness lucrative CAGR from 2024 to 2032 due to the surging government support. The focus on painless, convenient, and cost-effective vaccination methods in the region is making microneedle vaccines a promising solution for improving public health outcomes. The presence of a large and diverse population with varying levels of access to healthcare will also favor the product preference in APAC.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of influenza and viral infections
  - 3.2.1.2 Ease of administration
  - 3.2.1.3 Growing investment in research and development of microneedle technology
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Complications and risks associated with microneedles
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Pipeline analysis
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Solid microneedle
5.3 Hollow microneedle
5.4 Coated microneedle
5.5 Dissolving microneedle

Chapter 6 Market Estimates and Forecast, By Vaccine Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Trivalent flu vaccine
6.3 Quadrivalent flu vaccine

Chapter 7 Market Estimates and Forecast, By Flu Type, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Influenza A
- 7.2.1 H1N1
- 7.2.2 H3N1
7.3 Influenza B

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 South Africa
- 8.6.2 Saudi Arabia
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa